Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amaury Leruste

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Bulletin Du Cancer|December 18, 2021
CAR-T cells for pediatric brain tumors: Present and futureAmaury Leruste, Kevin Beccaria, François Doz
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 17, 2022
Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back AgainAdrienne H Long, Daniel A Morgenstern, Amaury Leruste, et al.
Tumori|April 20, 2021
Controversies on the possible role of immune checkpoint inhibitors in pediatric cancers: balancing irAEs and efficacyOlga Nigro, Andrea Ferrari, Michela Casanova, et al.
Bulletin Du Cancer|July 26, 2025
[Treatment guidelines for patients with relapsed/progressive high-risk neuroblastoma from the Neuroblastoma Committee of the French Society of Pediatric Oncology]Pablo Berlanga, Claudia Pasqualini, Marion Gambart, et al.
Journal of Pediatric Hematology/Oncology|January 29, 2022
Epstein-Barr Virus in Childhood and Adolescent Classic Hodgkin Lymphoma in a French Cohort of 301 PatientsVictor Pereira, Sabah Boudjemaa, Caroline Besson, et al.
Haematologica|March 3, 2022
Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective studyMarie Emilie Dourthe, Aurélie Phulpin, Anne Auperin, et al.
British Journal of Haematology|February 18, 2026
Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real-world studyMarlène Pouthier, Nathalie Garnier, Amaury Leruste, et al.
Pediatric Blood & Cancer|October 22, 2024
Outcome of childhood ALK-positive anaplastic large cell lymphoma relapses: Real-life experience of the French Society of Pediatric Oncology (SFCE) cohort of 75 French childrenVictor Pereira, Maël Barthoulot, Nathalie Aladjidi, et al.
Oncotarget|April 22, 2017
Embryonic signature distinguishes pediatric and adult rhabdoid tumors from other SMARCB1-deficient cancersWilfrid Richer, Julien Masliah-Planchon, Nathalie Clement, et al.
Cell Reports|November 16, 2017
High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid TumorsCéline Chauvin, Amaury Leruste, Arnault Tauziede-Espariat, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Bulletin Du Cancer|December 18, 2021
CAR-T cells for pediatric brain tumors: Present and futureAmaury Leruste, Kevin Beccaria, François Doz
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 17, 2022
Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back AgainAdrienne H Long, Daniel A Morgenstern, Amaury Leruste, et al.
Tumori|April 20, 2021
Controversies on the possible role of immune checkpoint inhibitors in pediatric cancers: balancing irAEs and efficacyOlga Nigro, Andrea Ferrari, Michela Casanova, et al.
Bulletin Du Cancer|July 26, 2025
[Treatment guidelines for patients with relapsed/progressive high-risk neuroblastoma from the Neuroblastoma Committee of the French Society of Pediatric Oncology]Pablo Berlanga, Claudia Pasqualini, Marion Gambart, et al.
Journal of Pediatric Hematology/Oncology|January 29, 2022
Epstein-Barr Virus in Childhood and Adolescent Classic Hodgkin Lymphoma in a French Cohort of 301 PatientsVictor Pereira, Sabah Boudjemaa, Caroline Besson, et al.
Haematologica|March 3, 2022
Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective studyMarie Emilie Dourthe, Aurélie Phulpin, Anne Auperin, et al.
British Journal of Haematology|February 18, 2026
Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real-world studyMarlène Pouthier, Nathalie Garnier, Amaury Leruste, et al.
Pediatric Blood & Cancer|October 22, 2024
Outcome of childhood ALK-positive anaplastic large cell lymphoma relapses: Real-life experience of the French Society of Pediatric Oncology (SFCE) cohort of 75 French childrenVictor Pereira, Maël Barthoulot, Nathalie Aladjidi, et al.
Oncotarget|April 22, 2017
Embryonic signature distinguishes pediatric and adult rhabdoid tumors from other SMARCB1-deficient cancersWilfrid Richer, Julien Masliah-Planchon, Nathalie Clement, et al.
Cell Reports|November 16, 2017
High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid TumorsCéline Chauvin, Amaury Leruste, Arnault Tauziede-Espariat, et al.
Pageof 3